WHO Proposes Regulatory Flexibilities For Testing MAbs Against Infectious Diseases
Executive Summary
A draft guideline from the World Health Organization intends to clarify regulatory expectations for the assessment of mAbs used for preventing and treating infectious diseases in health emergencies and to help with international harmonization efforts in this field.
You may also be interested in...
EU Falsified Medicines Directive ‘Not Working’ In Northern Ireland
Industry representatives told a House of Lords committee about continuing Brexit-related problems such as the extra work involved in checking compliance with the EU Falsified Medicines Directive and the drawbacks of a proposed “dual regulatory regime.”
UK Regulator Says April Fee Rise Will Support 'Innovative & Efficient' Service
The Medicines and Healthcare products Regulatory Agency says that the fee increases to be introduced on 1 April, along with 18 new fees, are necessary for its long-term financial sustainability and its ability to provide a “responsive, innovative and efficient regulatory service.”
Regulatory Flexibilities Help Ease EU Amoxicillin Shortages
The European Medicines Agency says that the current shortage of antibiotics containing amoxicillin is not a “major event” and that efforts by EU and national regulators are helping to mitigate the situation.